LRRK2 Mouse Models: Dissecting the Behavior, Striatal Neurochemistry and Neurophysiology of PD Pathogenesis
Overview
Authors
Affiliations
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD), resembling the sporadic disorder. Intensive effort has been directed toward LRRK2 mouse modeling and investigation, aimed at reproducing the human disease to inform mechanistic studies of pathogenesis and design of neuroprotective therapies. The physiological function of LRRK2 is still under exploration, but a clear role in striatal neurophysiology and animal behavior has emerged. Alterations in LRRK2 impair dopamine (DA) transmission, regulation and signaling, in addition to corticostriatal synaptic plasticity. Consistently, several subtle abnormalities in motor and nonmotor abilities have been demonstrated in LRRK2 genetic mouse models, generally paralleling preclinical symptoms of early DA dysfunction. However, the variability in model design and phenotypes observed requires a critical approach in interpreting the results, adapting the model used to the specific research question. Etiologically appropriate knockin mice might represent the ultimate animal model in which to study early disease mechanisms and therapies as well as to investigate drug effectiveness and off-target consequences.
Ngo H, Srivastava A, Le H, Ayer S, Crotty G, Schwarzschild M BMC Neurosci. 2025; 26(1):19.
PMID: 40038582 PMC: 11877714. DOI: 10.1186/s12868-025-00939-7.
Astrocytic LRRK2 Controls Synaptic Connectivity via Regulation of ERM Phosphorylation.
Wang S, Baumert R, Sejourne G, Bindu D, Dimond K, Sakers K bioRxiv. 2024; .
PMID: 39253496 PMC: 11383028. DOI: 10.1101/2023.04.09.536178.
LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons.
Chen C, Masotti M, Shepard N, Promes V, Tombesi G, Arango D bioRxiv. 2024; .
PMID: 38895420 PMC: 11185612. DOI: 10.1101/2024.06.06.597594.
Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson's Disease.
Saponjic J, Mejias R, Nikolovski N, Dragic M, Canak A, Papoutsopoulou S Int J Mol Sci. 2024; 25(8).
PMID: 38673915 PMC: 11050170. DOI: 10.3390/ijms25084330.
Ngo H, Le H, Ayer S, Crotty G, Schwarzschild M, Bakshi R Res Sq. 2024; .
PMID: 38562908 PMC: 10984011. DOI: 10.21203/rs.3.rs-4076333/v1.